A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
NCT06638307 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240
Last updated 2026-05-12
Summary
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Conditions
Interventions
- DRUG
-
MEN2312
MEN2312 administered as oral tablets.
- DRUG
-
Elacestrant
Elacestrant administered as oral tablets.
Sponsors & Collaborators
-
Stemline Therapeutics, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-10-25
- Primary Completion
- 2026-06-30
- Completion
- 2026-10-31
- FDA Drug
- Yes
Countries
- United States
- Spain
Study Locations
More Related Trials
-
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
NCT02750358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
NCT02833155 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
NCT01889238 ·Status: COMPLETED ·Phase: PHASE2
-
An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer
NCT03243331 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
NCT02708680 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948 ·Status: RECRUITING ·Phase: PHASE3
-
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
NCT06062498 ·Status: RECRUITING ·Phase: PHASE2
-
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546 ·Status: RECRUITING ·Phase: PHASE2
-
Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT00574366 ·Status: COMPLETED ·Phase: PHASE1
-
Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00030537 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
NCT03291886 ·Status: COMPLETED ·Phase: PHASE2
-
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer
NCT03078751 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT06997029 ·Status: RECRUITING ·Phase: PHASE1
-
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
NCT00739063 ·Status: TERMINATED ·Phase: PHASE2
-
Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
NCT00255788 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
NCT02929576 ·Status: WITHDRAWN ·Phase: PHASE3
-
Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer
NCT02115594 ·Status: WITHDRAWN ·Phase: PHASE2
-
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers
NCT05986071 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer
NCT05065411 ·Status: TERMINATED ·Phase: PHASE3
-
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03579472 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
NCT02763566 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
NCT02053636 ·Status: COMPLETED ·Phase: PHASE2
-
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
NCT02037529 ·Status: SUSPENDED ·Phase: PHASE3